VIVUS to Present at the 2010 JP Morgan Healthcare Conference

Jan 05, 2010, 07:00 ET from VIVUS, Inc.

MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 28th Annual JP Morgan Healthcare Conference.

The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Monday, January 11, 2010 at 8:00 a.m. PT. A live webcast and 30-day archive of the presentation will be available at


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit


    VIVUS, Inc.           Investor Relations:          The Trout Group
    Timothy E. Morris                                  Brian Korb
    Chief Financial
     Officer                                           646-378-2923
    Media Relations:      Pure Communications, Inc.
    Dan Budwick